Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.56 |
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | PPARD | Q03181 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15446337 | 0.84 | SRR (0.60) | PPARAPPARGTSHRPNMT | |
| SCHEMBL18039176 | 0.83 | PPARG (0.81) | PPARAPPARG | |
| SCHEMBL29406517 | 0.81 | PPARA (0.68) | PPARAPPARGPPARD | |
| SCHEMBL23933856 | 0.79 | PPARA (0.54) | PPARAPPARGPPARDPNMT | |
| SCHEMBL23933859 | 0.79 | PPARA (0.54) | PPARAPPARGPPARDPNMT | |
| SCHEMBL4439324 | 0.79 | PNMT (0.53) | PPARAPPARGTSHRPNMTLDHA | |
| SCHEMBL20420631 | 0.79 | KDM6B (0.60) | PPARAPPARGPPARDTSHRMMP1 | |
| SCHEMBL5607348 | 0.78 | PPARA (0.55) | PPARAPPARGPPARDLDHAFFAR1 | |
| SCHEMBL5130053 | 0.78 | PNMT (0.58) | PPARAPPARGPPARDTSHRPNMT | |
| SCHEMBL6003855 | 0.78 | PNMT (0.58) | PPARAPPARGPPARDTSHRPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | PPARA 350/4885PPARG 255/4885PPARD 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.